Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab.
نویسندگان
چکیده
, 81 infliximab naive RA patients and 47 healthy subjects as controls. At the same time and apart from the purposes of that study, we also had done a pathergy test in those subjects who agreed to participate, with the aim of determining the effect of the pathergy phenomenon on the response of BS patients to the tuberculin test. Informed consent was obtained from all subjects. The study was approved by the ethical committee of Istanbul University, Cerrahpasa Medical School. Eighty BS and 61 RA patients and 38 healthy controls participated. The tuberculin test was administered with the Mantoux technique, using 5 IU of purified protein derivative (PPD) solution, which was injected intradermally into the forearm by a nurse. The pathergy test was done at three sites on each forearm by inserting six sterile 20-gauge needles intradermally, on the same day as the tuberculin test. Both the tuberculin test and the pathergy reaction were evaluated 48 h later, by two independent observers in a blinded manner. Subjects put their arms through a curtain and their hands were covered to prevent the observers from recognizing the subjects, or any deformities revealing the diagnosis. PPD reaction was evaluated by measuring the transverse diameter of the induration. A positive pathergy test was defined as a papule or a pustule at the insertion site of the needle. The number of subjects with a positive PPD test (!10 mm) in each group was compared and the relationship between PPD positivity and the pathergy phenomenon was sought. The number of patients with a positive pathergy reaction, a positive PPD test and the mean PPD induration of each group are shown in Table 1. The mean diameter of the PPD induration was lower among RA patients (H 2df ¼ 20.1, P < 0.001, Kruskal–Wallis) when compared with BS patients and healthy controls. The mean indurations in BS patients and healthy controls were similar (H 1df ¼ 2.0, P ¼ 0.163, Kruskal–Wallis). Inter-group comparisons revealed that mean PPD induration was similar among BS patients and healthy controls (Mann–Whitney U ¼ 1207, P ¼ 0.163). PPD indurations in both BS patients and healthy controls were higher than in RA patients (Mann–Whitney U ¼ 1595, P < 0.001 and Mann–Whitney U ¼ 568.5, P < 0.001, respectively). The number of patients with a positive PPD was also lower among RA patients than the other two groups (2 ¼ 19.246, P …
منابع مشابه
Sustained Remission After Combination Therapy with Rituximab and Etanercept in Two Patients with Rheumatoid Arthritis After TNF Failure: Case Report
OBJECTIVES Approximately up to 40% of patients with rheumatoid arthritis (RA) fail to respond to tumor necrosis factor (TNF) inhibitors, lose response over time or are unable to tolerate treatment. MATERIALS AND METHODOLOGY We report two female patients suffering from active, refractory rheumatoid arthritis despite TNF blocking agents who have been treated with rituximab added to ongoing ther...
متن کاملB-cell depletion with rituximab as treatment for immune hemolytic anemia and chronic thrombocytopenia.
BACKGROUND AND OBJECTIVES Rituximab reacts specifically with the CD20 antigen and induces B-cell depletion. This could interfere with the production of autoantibodies in some immune diseases. The objective of this study was to assess the effects of rituximab in autoimmune hemolytic anemia and thrombocytopenia. DESIGN AND METHODS Seven patients (one with cold agglutinin disease, two with warm ...
متن کاملComparison of Biologic Disease-Modifying Antirheumatic Drug Therapy Persistence Between Biologics Among Rheumatoid Arthritis Patients Switching from Another Biologic
INTRODUCTION To compare biologic disease-modifying antirheumatic drug therapy persistence between biologics among patients with rheumatoid arthritis (RA) who previously used ≥1 other biologic. METHODS Using a large United States administrative claims dataset, we identified adult patients with RA initiating abatacept, adalimumab, certolizumab, etanercept, golimumab, infliximab, or tocilizumab ...
متن کاملRituximab is a therapeutical option for juvenile microscopic polyangiitis
Introduction Microscopic polyangitiis is characterized by anti-neutrophil cytoplasmic antibodies (ANCA) and small vessel vasculitis. The diseases usually respond to cyclophosphamide (Cyc) but some patients are therapy resistant. Rituximab (RIT) is a chimeric antibody to CD20 causing lysis of B-lymphocytes and used for treatment of lymphomas. RIT has also been successfully used in patients with ...
متن کاملEvaluation of the efficacy and safety of rituximab in patients with refractory pemphigus vulgaris
Background: Recently, rituximab has been successfully used for the treatment of pemphigus family, the main subtype of which is pemphigus vulgaris (PV). The aim of this study was to determine the efficacy and safety of rituximab in refractory PV. Methods: In an observational study extending from November 2014 to February 2016, 30 patients with refractory PV were treated with rituximab. Response ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید
ثبت ناماگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید
ورودعنوان ژورنال:
- Rheumatology
دوره 47 5 شماره
صفحات -
تاریخ انتشار 2008